Replies to post #425711 on NorthWest Biotherapeutics Inc (NWBO)

[JRIII]

The reason they are not releasing the data has nothing to do with a journal. They could release TLD any time they want. They've been unblinded since October 2020.

The reason they are refusing to release the data is because it is bad. That's right, the data is bad. I mean, could it not be more obvious? What else could they possibly be (not) doing to make people realize this is a failed trial, and that you can't change endpoints after conducting a trial for 16 years, and you can't use historical controls to make valid comparisons? It is a failure. That is why they haven't even bothered to update the trial register. Failure is BY FAR the most likely and plausible explanation for why we haven't seen the data.

They are waiting on certification for Sawston to announce it. That makes perfect sense. You don't want to announce the trial failed now, before you get certification, because everything could collapse. But if you wait until you have certification, then you have something to fall back on (at least for Advent) and it is highly unlikely that everything would collapse.

Unfortunately, when that happens, I think there's a good chance NWBO shareholders will be left on the sideline as Advent ramps up into a full-scale manufacturing operation - like Cognate did before it sold for $800 million. Believe me when I tell you that sale got her attention. When she saw that Cognate sold for $800 million just a couple years after she had sold it for a lot less, I think a light bulb went off in her head. She doesn't need this failed vaccine anymore, and she doesn't need NWBO shareholders anymore, either.

[Umibe5690]

Hi FeMike:

First, thank you for your comments. The points you make may well be valid.

However, my point was that I don’t agree with your statement that LP does not know what she is doing which is tantamount to calling her incompetent.

I don’t think any of us on this MB can conclude this. We do not sit where she does. We don’t have the facts she has. We don’t have her experience. We very likely don’t have her brain power. We certainly don’t have the phalanx of advisors she has. We don’t work at NWBO every day. We don’t have her resources. We don’t have the opportunity for collaborative decision making that she has. Accordingly, I think it quite unlikely that she is incompetent.

While I don’t like the deafening silence, missed guidelines, etc., this does not mean that well considered reasoning is lacking. Perhaps if I knew what she knows with benefit of her team of advisors, I would have made the same decisions. Who knows.

I don’t claim that she has not made mistakes. However, on the major strategic issues and decisions, these are assuredly well thought out and vetted with her counselors. In hindsight these decisions may not have been correct or even the best way to move forward, but they were well considered at the time and not incompetent decisions. To be sure not all company issues and operations involve such elaborate collaboration. Timeline guidance may have been one of them. I think that management wanted to throw shareholders a bone. I think counsel probably told them, OK, in the interest of investor relations but with all the caveats. However, continuing to miss the mark, probably they all came to the conclusion that due to external factors not under their control which significantly impacted their prognostications, they opted for silence and “don’t explain other than we are in a quiet period.”

LP has brought the company to where it is today on the brink of announcing what I think will be remarkable data and a new paradigm for SOC wrt the king of cancers. And she has done so in the face of daunting challenges where lesser resolute leaders may have given up. Has she made mistakes? Maybe. But incompetent? That is much too extreme a judgement. To repeat, we don’t sit where she does. Accordingly, the least we can say is to withhold judgement as, if and when she brings the company across the goal line. From what I see, overall, I give her the benefit of any doubt and firmly believe that her overall management will lead to success for patients and investors.

GLTU whatever you decide.

[skitahoe]

Iron Mike,

If TLD were revealed I would certainly hope the share price was many times the current price, not just a double. As I remember the high set over a year ago it was $2.51, I believe double that or more is very possible on TLD especially if it's timed to have the Journal a short time thereafter, and they say so.

I agree with Umibe, if you've been in our CEO's shoes you might give her more credit for how far she's brought the company. I believe that she can take it the rest of the way through approval, if she so chooses. I don't know that a partnership, or buyout, isn't possible before approval, but success will be assured whether it is, or isn't.

Gary

[biosectinvestor]

Honestly, it is quite obvious why. It is a trial with enough anomalous circumstances, though not affecting the validity of the results in truth, but enough to allow bad actors to make a mess of things if it is purely a commercial presentation of the results. Announcing TLD is nothing more than a commercial company saying what they believe and shorts KNOW this to be true and seem almost outraged that a journal article will undermine what was always obviously the strategy. They will no doubt still try, but a journal article versus whatever they throw at it, will be imperative their grenades. Their critiques will seem either competitive bad blood or commercial bad acts, even if hidden behind a “scientist”.

That is the reality.

Meanwhile, the DOJ has opened a serious investigation and I doubt this situation would be immaterial.